Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Neoadjuvant Chemotherapy of Gemcitabine+Nab-paclitaxel Therapy for Patients With Borderline Resectable Pancreatic Cancer

NCT02926183 is registered in ClinicalTrials.gov with Wakayama Medical University as lead sponsor.

NCT NCT02926183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02926183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Neoadjuvant Chemotherapy of Gemcitabine+Nab-paclitaxel Therapy for Patients With Borderline Resectable Pancreatic Cancer
Lead sponsor
Wakayama Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2016
Completion date
September 30, 2021
Enrollment
60 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma